SOURCE: Maybach Financial Group

Maybach Financial Group

October 12, 2007 13:46 ET

Maybach Financial Group: The Biotech Frontier Focusing on Immunogen Inc., Cyclacel Pharmaceuticals Inc., and Accentia Biopharmaceuticals Inc.

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Maybach.

GRANDE BAY, MAURITIUS--(Marketwire - October 12, 2007) - Comments made in this release are those of Maybach Financial Group and any questions or comments should be directed to the contact information located at the bottom of this release.

Maybach Financial Group is a syndicate of financial analysts, with a core group representing over 250 years of total investing experience. Our focus is to give investors the financial advantage necessary to sustain profit all markets. This week, to gauge the outcome of the markets, we are focusing on Immunogen Inc. (NASDAQ: IMGN), Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC), and Accentia Biopharmaceuticals Inc. (NASDAQ: ABPI). For the full report, visit

The Maybach Financial Group will be researching the above-mentioned companies to determine their chances of a turnaround opportunity for investors. Visit for a complimentary subscription to the Maybach service and receive at no cost our "Special Report#1: The Pick of the Decade" plus a second free report "Special Report #2: Hearing is Believing." No credit card or payment information is required.

The golden age of biotech is before us. Recent advances in genetics fuel products that will create more value in the 21st century than the Internet. Learning about biotechnology will not only benefit us as investors, it will help us understand a revolution affecting our daily lives.

Research and development in the pharmaceuticals and biopharmaceuticals sector play a strong role in revolutionizing the way illnesses are prevented, diagnosed, treated and cured. Contributors to these efforts are found throughout the sector's major segments, which include brand-name drug manufacturers, generic drug manufacturers, firms developing bio-pharmaceutical products, non-prescription drug manufacturers, and firms undertaking research on a contract basis.

Although biotechnology is not an area in which typical traditional exporting takes place, there is a lot of room for strategic partnering and technology transfer. Possibilities include R&D collaboration, in- and out-licensing of technologies, product development, venture-capital funding and joint ventures.

Antibodies have been proven as excellent tools for specifically targeting cancer cells, however, the damage they inflict upon cancer cells is minimal, especially when compared with chemotherapy drugs. One such company that has a bright outlook in this area is Immunogen Inc. (NASDAQ: IMGN). The company focuses on developing monoclonal antibodies. However, companies that specialize in developing immunoconjugates, instead of just "naked" antibodies, represent a more lucrative opportunity. And when it comes to investing in such pure-plays, it doesn't get any better than Immunogen.

While, Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) is a 10-year old company dedicated to the discovery, development and commercialization of novel, targeted drugs to treat human cancers and other serious disorders. Their vision is that such novel targeted drugs enable cancer sufferers to hopefully control their disease and live a normal lifespan, like the experience of the people who have diabetes today.

And lastly, things are really beginning to heat up at Accentia Biopharmaceuticals (NASDAQ: ABPI) these days. This Monday, the Tampa Florida company announced their completion of enrollment of their ongoing FDA fast-tracked Phase-3 trial for their lead compound, Sinunase, for the treatment of Chronic Rhino Sinusitis.

One final note to contemplate in regards to Biotechnolgy stocks is that Biotechnology is not an industry. It is a technology. There is no "biotechnology industry," per se -- just as there is no "Internet industry." There are many, many companies that use biotechnology or the Internet in order to profit, providing products or services that customers find attractive and valuable. But just try to identify a single "top dog" Internet or biotechnology company. It's not really possible. Again, these are technologies that different companies adopt in order to gain a lead in one industry or another.

Visit to receive our Special Report #1 with information on how technology will change the face of this world.

Maybach isn't about day-trading and making money fast. It's about being patient and learning the secret of how to get rich slowly. Visit to receive TWO free special reports.

It's also about adding stocks to your portfolio that have little or no effect against the state of the economy.

It's about technology

For a limited time only, gain access to Maybach and our reports free of charge with no credit card or payment information required. Visit for your free subscription.

Maybach Financial (Maybach) is not a registered broker dealer or a registered investment advisor. No information accessed through the Maybach Web site or this release constitutes a recommendation to buy, sell or hold any security in any jurisdiction. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. There is no financial relationship that exists between the issuer of this release and the company whose stock is mentioned in the release. Please view the disclaimer at

Statements made in this release may include forward-looking statements and projections, made in reliance on the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Maybach has made every reasonable effort to ensure that the information and assumptions on which these statements and projections are based are current, reasonable, and complete. However, a variety of factors could cause actual results to differ materially from the projections, anticipated results or other expectations expressed in this release. Maybach makes these statements and projections in good faith, neither Maybach nor its management can guarantee that the transactions will be consummated or that anticipated future results will be achieved. All material herein was based upon information believed to be reliable. The information contained herein is not guaranteed by Maybach to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Maybach assumes no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by Maybach, whether as a result of new information, future events, or otherwise.

Contact Information

    The Maybach Financial Group
    Toll Free: 1-800-344-4888
    Email: Email Contact